| Not Yet Recruiting | Phase 1 Study of PF-08046033 in Advanced Solid Tumors NCT07519655 | Pfizer | Phase 1 |
| Recruiting | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanom NCT06319196 | University Health Network, Toronto | Phase 2 |
| Recruiting | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) NCT06999980 | Melanoma Institute Australia | Phase 2 |
| Not Yet Recruiting | A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients NCT07068074 | Eastern Cooperative Oncology Group | Phase 3 |
| Recruiting | Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma NCT07148245 | University of California, San Francisco | — |
| Recruiting | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma NCT06624644 | Linnaeus Therapeutics, Inc. | Phase 2 / Phase 3 |
| Recruiting | ACTengine® IMA203 Combined With mRNA-4203 NCT06946225 | Immatics US, Inc. | Phase 1 |
| Active Not Recruiting | Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma o NCT06984328 | Genmab | Phase 2 |
| Recruiting | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers NCT06967961 | Institut Claudius Regaud | N/A |
| Recruiting | Melanoma of the Skin and Exposure to Solar Ultraviolet Radiation at Work in Modena Territory: a Case-control S NCT07251335 | University of Modena and Reggio Emilia | — |
| Recruiting | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962 | Radiopharm Theranostics, Ltd | EARLY_Phase 1 |
| Active Not Recruiting | Exercise to Boost Response to Checkpoint Blockade Immunotherapy NCT06008977 | AdventHealth Translational Research Institute | N/A |
| Recruiting | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases NCT06194929 | University of Utah | Phase 1 / Phase 2 |
| Unknown | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma NCT04702854 | Centre Hospitalier Universitaire de Nice | N/A |
| Recruiting | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymph NCT06223659 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Recruiting | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT05970497 | Krystal Biotech, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents NCT06090266 | OncoResponse, Inc. | Phase 1 / Phase 2 |
| Recruiting | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform NCT05520099 | Elephas | — |
| Recruiting | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Co NCT05824975 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Completed | Enhancing Skin Cancer Early Detection and Treatment in Primary Care NCT05675709 | OHSU Knight Cancer Institute | N/A |
| Recruiting | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tu NCT05669430 | GV20 Therapeutics | Phase 1 / Phase 2 |
| Terminated | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors NCT05576077 | Turnstone Biologics, Corp. | Phase 1 |
| Active Not Recruiting | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors NCT05571839 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1 NCT05578872 | Anaveon AG | Phase 1 / Phase 2 |
| Completed | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma NCT05628883 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advance NCT05544929 | Novartis Pharmaceuticals | Phase 1 |
| Withdrawn | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 NCT05482074 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Exercise to Boost Response to Checkpoint Blockade Immunotherapy NCT05358938 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Unknown | Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive NCT04253080 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unrese NCT05267626 | Aulos Bioscience, Inc. | Phase 1 / Phase 2 |
| Recruiting | The MELAcare Study: A New Method for Surveillance of Melanoma Patients NCT05253872 | Herlev and Gentofte Hospital | N/A |
| Terminated | RTX-224 Monotherapy in Patients With Solid Tumors NCT05219578 | Rubius Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health Sy NCT07376317 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Terminated | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Muco NCT04830124 | Mural Oncology, Inc | Phase 2 |
| Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444 | Guardant Health, Inc. | — |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours NCT04855435 | MonTa Biosciences ApS | Phase 1 |
| Active Not Recruiting | TH1902 in Patients With Advanced Solid Tumors NCT04706962 | Theratechnologies | Phase 1 |
| Active Not Recruiting | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma NCT03929029 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positiv NCT04551352 | Hoffmann-La Roche | Phase 1 |
| Active Not Recruiting | Neoadjuvant Atezolizumab in Cutaneous Melanoma NCT04020809 | The Methodist Hospital Research Institute | Phase 1 |
| Terminated | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer NCT04254107 | Seagen Inc. | Phase 1 |
| Terminated | A Study of SGN-CD228A in Advanced Solid Tumors NCT04042480 | Seagen Inc. | Phase 1 |
| Recruiting | Neoadjuvant Combination Immunotherapy for Stage III Melanoma NCT03842943 | University of Louisville | Phase 2 |
| Recruiting | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions NCT03947385 | IDEAYA Biosciences | Phase 1 / Phase 2 |
| Completed | A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery NCT03843593 | Memorial Sloan Kettering Cancer Center | — |
| Completed | MGD019 DART® Protein in Unresectable/Metastatic Cancer NCT03761017 | MacroGenics | Phase 1 |
| Completed | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma NCT03620019 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas NCT03611868 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Completed | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine NCT03633110 | Genocea Biosciences, Inc. | Phase 1 / Phase 2 |
| Terminated | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma NCT03699995 | OHSU Knight Cancer Institute | N/A |
| Active Not Recruiting | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) NCT03767348 | Replimune, Inc. | Phase 2 |
| Terminated | Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma NCT02968680 | University of Southern California | Phase 1 |
| Completed | Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases NCT03628417 | Szeged University | N/A |
| Completed | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced R NCT02791334 | Eli Lilly and Company | Phase 1 |
| Completed | A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope) NCT02831634 | Institut Curie | N/A |
| Completed | Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Manag NCT04789421 | Azienda Ospedaliero-Universitaria di Modena | N/A |
| Completed | Neoadjuvant and Adjuvant Checkpoint Blockade NCT02519322 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma NCT04778449 | M.D. Anderson Cancer Center | — |
| Terminated | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma NCT02288897 | Provectus Biopharmaceuticals, Inc. | Phase 3 |
| Recruiting | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome NCT04792463 | Mohamed Abdel-Rahman | — |
| Terminated | 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results NCT02355574 | Castle Biosciences Incorporated | — |
| Completed | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV NCT02129075 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Pa NCT02355587 | Castle Biosciences Incorporated | — |
| Completed | Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma NCT04274816 | A.J.M. van den Eertwegh | Phase 1 |
| Active Not Recruiting | Minimal SN Tumor Burden NCT01942603 | European Organisation for Research and Treatment of Cancer - EORTC | — |
| Unknown | Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Pat NCT01729663 | Laboratorio Pablo Cassará S.R.L. | Phase 2 / Phase 3 |
| Completed | miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi NCT01444560 | Ruhr University of Bochum | — |
| Completed | Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma NCT00679289 | Ludwig Institute for Cancer Research | Phase 2 |
| Unknown | Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor. NCT04625491 | Hospital Universitario Virgen de la Arrixaca | — |
| No Longer Available | Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets NCT01728051 | Delcath Systems Inc. | — |